
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is positioned for substantial growth as it enhances its AI-powered ECG diagnostic solutions, aiming to revolutionize cardiac screening in various healthcare settings. The company has raised its FY26 EPS estimate due to lower expenses, reflecting improved operational efficiency, while an increase in outstanding shares from 0.9 million to 3.2 million indicates robust equity financing to support its expansion. With a new price target of $9.20 based on a net present value analysis, HeartSciences demonstrates a strong potential for scalability, akin to a tolling model similar to app stores, further underpinning its positive financial outlook.
Bears say
HeartSciences Inc. is facing significant challenges that contribute to a negative outlook for its stock, primarily due to a lack of visibility regarding the timing of commercial revenues, leading to revised revenue estimates of $0.0 million for FY2026 and $0.4 million for FY2027. Additionally, operating expenses were reported at $2.1 million, only slightly below the estimated $2.2 million, which raises concerns about financial efficiency amid stagnant revenue projections. Further risks include potential issues with product safety and efficacy, regulatory approvals, commercialization efforts, reimbursement processes, and market competition, all of which indicate underlying financial vulnerabilities for the company.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares